SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?


To: Timothy Kross who wrote (120)7/12/1998 12:09:00 PM
From: Biomaven  Respond to of 626
 
Tim,

I would assume (but am not sure) that Titan would owe a royalty to HMR for any Japanese sales. Novartis is paying the required HMR royalty and milestone payments directly to HMR.

Peter



To: Timothy Kross who wrote (120)7/12/1998 10:31:00 PM
From: Scott H. Davis  Read Replies (1) | Respond to of 626
 
That would be true if they decide to market themselves. Some biotechs
are pursuing a hybrid stratedgy (VICL, LGND) licensing some, retaining others. AGPH is going it alone. Anybody know what TTNP's stratedgy is in this regard?